key: cord-0756053-ri3usztz
authors: Chang, Cheng-Wei; Liu, Yuchen; Jiao, Cheng; Liu, Hongwei; Chen, Xiaochuan; Chang, Lung-Ji
title: A glimpse into the diverse cellular immunity against SARS-CoV-2
date: 2021-02-18
journal: bioRxiv
DOI: 10.1101/2021.02.17.431750
sha: e2af3b6145e49a3422411361722a6fe0a6975dbf
doc_id: 756053
cord_uid: ri3usztz

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific cellular immune response may prove to be essential for long-term immune protection against the novel coronavirus disease 2019 (COVID-19). To assess COVID-19-specific immunity in the population, we synthesized selected peptide pools of SARS-CoV-2 structural and functional proteins, including Spike (S), Membrane (M), Envelope (E), Nucleocapsid (N) and Protease (P) as target antigens. Survey of the T cell precursur frequencies in healthy individuals specific to these viral antigens demonstrated a diverse cellular immunity, including high, medium, low and no responders. This was further confirmed by in vitro induction of anti-SARS-CoV-2 T cell immune responses using dendritic cell (DC)/T cell coculture, which supported the corresponding T cell precursor frequencies in each of the individuals tested. In general, the combination of all five viral antigen pools induced the strongest cellular immune response, yet individual donors responded differently to different viral antigens. Importantly, in vitro restimulation of the T cells with the DC-peptides induced increased anti-viral immune responses in all individuals even in the no responders, suggesting that repeated antigen stimulation could elicit a broad protection in immune naïve population. Our analysis recapitulates the critical role of cellular immunity in fighting COVID-19 and the importance of analyzing anti-SARS-CoV-2 T cell response in addition to antibody response in the population. Importance Facing the rapid evolving SARS-CoV-2 variants in the world, current emphasis on antibody-producing vaccines needs a quick revisit. The virus-specific cellular immunity may prove to be essential for long-term protection against COVID-19. This study designed a series of antigenic peptides encompassing the conserved and/or essential domains of Spike (S), Membrane (M), envelope (E), Nucleocapsid (N) and Protease (P) as targets to assess Covid-19-specific immunity in the population. The results demonstrated a diverse cellular immunity, including high, medium, low and no responders. This was verified by in vitro generation of anti-SARS-CoV-2 T-cells from these subjects. The study suggested that individuals responded differently to the different viral antigens, and importantly, repeated stimulation could produce virus specific T cells in all individuals, including the no responders. This study illustrates the needs for assessing anti-viral cellular immunity in addition to antibody response in the general population.

Introduction 7 functional importance, and the pentadeca-peptides can induce both class I and class II 126

Antigen-specific immune effector cells can be generated through antigen 128 presentation by DCs. The protocol includes in vitro generation of DC, followed by 129 antigen exposure and co-culture with autologous lymphocytes. We isolated peripheral 130 mononuclear cells (PBMCs) from healthy volunteers, and generated matured DCs 131 from monocytes. The specific antigen pools of SARS-CoV-2 were used to pulse DCs 132 and then cocultured with peripheral blood lymphocyts to activate antigen-specirtic T 133 cells as illustrated in Figure 1c . To investigate the frequency of immune effectors to SARS-CoV-2 in healthy 138 individuals, we examined antigen-specific T cells in 29 healthy subjects who have no 139 known prior exposure to the SARS-CoV-2. PBMCs were isolated from the whole 140 blood, and the pooled viral S, M, E, N and P peptides, as well as a control HIV 141 peptide pool, were added to the PBMCs to activate immunogenic response for 17 142 hours, followed by IFN-γ ELISPOT analysis. The IFN- specific spots represented the 143 antigen-specific T cells activated by the peptide antigens. Positive response was 144 arbitrarily set at a 1.5-fold increase in the numbers of IFN-γ-secreting T cell spots in 8 the test wells versus the control wells which included PBMC alone or treatment with 146

We observed a diverse range of SARS-CoV-2-specific primary T cell frequencies 148 in the healthy population, presented as spot forming cells in Figure 2a (Raw data in 149

Supplementary Tables 1-3). After deducting the background value, the frequencies of 150 antigen specific T cells in 10 5 T cells to each peptide antigen pool for each subject are 151 plotted in Figure 2b , and the bars represent the median value of antigen-specific T 152 cells to each antigen pool. There was a trend that the five mixed peptide pools 153 (SMENP) revealed the highest T cell precursor frequencies as compared with the 154 individual viral peptide pools (Fig. 2b) . The antigen specific response was also 155 quantified based on the fold increase of spots with respect to the PBMC alone group. 156

We set the scales as low responders if the number was 1.5-2 fold higher than the antigenic target used in the COVID-19 vaccine design, is only 10%, similar to those 165 of the high responders to the M peptide pools. 166 167

To investigate whether T cells of different respondrers could be activated by the 169 SARS-CoV-2 antigens, we selected donors with different responses in the precursor 170 frequency test to perform an in vitro T cell activation assay. Immature DCs were 171 generated from adherent blood monocytic cells for 5 days in the presence of GM-CSF 172 and IL-4 (16). T cells were co-cultured with DCs pulsed with the various 173 SARS-CoV-2 antigenic peptides, including pooled SMENP and the individual viral 174 protein peptide pools, or a negative control HIV peptide pool, for 12 days, followed 175 by ELISPOT analyses. The results showed that the activation potential of the 176 individual antigen-specific T cells correlated with their corresponding T cell precursor 177 frequencies, i.e., the high responders developed the strongest T cell response, and the 178 no responders developed little to no response (Fig. 3a) . The high responder group 179 showed enhanced specific cellular immune response by more than 30 fold after 12 180 days in culture, and the medium responder group and low response group increased 181 about 15 folds and 10 folds, respectively. On the other hand, the expansion of the 182 antigen-specific T cells in the no responder group was relatively low (Fig. 3b) . Again, 183

there was a diversity in the individual preference in response to the various viral 184 antigens of SARS-CoV-2, e.g, the high responder had the lowest response to the E 185 antigen, whereas the no response donor #2 had the highest response to the E antigen. 186 187 Immune booster to enhance specific anti-viral cellular immunity 188

To see if the anti-viral immune response could be enhanced in the no responders 189 by an immune booster application, we re-stimulated the in vitro cultured T cells from 190 the two no responders with DCs pulsed with the same SARS-CoV-2 antigen peptide 191 pools, and extended the culture for 30 days. ELISPOT assay was then performed to 192 measure the specific T cell responses. As compared with the 12 day results, the 193 background value of the non-specific cells decreased significantly (Fig. 4a) , and the 194 specific expansion of T cells increased to more than 20 folds after the secondary 195 immune stimulation (Fig. 4b) . The result suggested that individuals with low 196 frequency of immune response to the SARS-CoV-2 virus could benefit from antigen 197 restimulation. 198 199

Upon T cell receptor (TCR) engagement and stimulation by antigens in 201 association with MHC molecules, specific immune effector functions can be 202 demonstrated by the activation and release of specific effector molecules such as 203 IFN-, TNF-α, . We examined the SARS-CoV-2 viral 204 antigen-specific T cell response by intracellular staining for TNF-α, IFN-, IL-2 and 205

CD107a. The generation of a SARS-CoV-2 specific T cell response was determined 206 by comparing T cell stimulation with a control HIV peptide pool. We observed 207 several folds of increases in the SARS-CoV-2 antigen-reactive T cells over the control 208 shown that many people infected with SARS-CoV-2 virus with mild synptoms or 218 asymptomatic status can develop T-cell-mediated immunity to the virus even without 219 antibody response (24). In addition, ananlysis of T cell immunity to specific 220 SARS-CoV-2 epitopes also demonstrates the existence of anti-viral T cells in 221 un-exposed individuals (25) (26) (27) . This means that the actual level of population 222 immunity to the new coronavirus is higher than antibody positive population. 223

In this study, we investigated SARS-CoV-2-specific cellular immunity in healthy 224 individuals who have no known exposure to the virus. Our results demonstrated that 12 approximately 60-70% of tested individuals have no cellular immune response to the 226 virus. About 20% of the tested subjects had T cell response to the virus, and a few of 227 them had strong cellular immune response to the virus. Note that many of the subjects 228 of this study came from Guandong province (13 of the 29), the epicenter of previous 229 SARS epidemic. Possible prior SARS-CoV exposure cannot be excluded. It is 230 anticipated that those with strong cellular immunity to the virus may become 231 asymptomatic or only have mild symptoms after exposure to the virus, as well as a 232 better prognosis, as reported by a clinical study that cellular immunity is associated 233 with recovery from 13) . The study subjects #4, #15 and #26 had high 234 precursor frequencies. After a retrospective survey, we discovered that subject 4, a 235 young individual who had lived in Guangzhou, China, during the SARS-CoV peak 236 epidemic in 2011, and this subject might have been exposed to the SARS virus at the 237 time. The subject #15 and #26 are 65 and 39 years old, respectively, and might have 238 been exposed to other common cold human endemic coronaviruses. The protein 239 sequences of SARS-CoV-2 share high homology to SARS-Cov and MERS (>90%), 240

and moderate homology to the other coronaviruses (28). The SARS-CoV-2 peptide 241 pools designed in this study encompassed several different viral proteins, which 242 include some highly conserved antigenic domains identical or similar to the other 243 coronaviruses (Supplementary Table 4 , CoV sequence homology comparison using 244

It is not surprising that there is a diversity in anti-viral cellular immunity as the 246 viral antigens are presented based on the individual HLA type. For example, it is 247 known that HLA-B27 individuals carry an HIV-resistant phenotype (29). It is also 248 possible that some individuals are highly suspectible to the SARS-CoV-2 infection, 249

while others may be more resistant to the virus. Importantly, our study showed that if 250 the immune cells were exposed to all five viral protein peptides, there was an 251 increased overall T cell response. The design of antigenic peptides spanned across the 252 entire protein domains which might have included regulatory T cell epitopes, and thus 253 inhibitory T cell responses could also be induced. This study included subjects from 254 both Southern and Northern Chinese population with high variation in HLA 255 phenotype. While HLA-restricted immunity plays a role in the antiviral response, to 256 further define HLA-specific SARS-CoV-2 response is out of the scope of this study. 257

Nevertheless, extended evaluation of viral effector and regulatory antigenic domains 258 will be helpful for anti-viral immunity studies. 259

The 29 subjects ranged from age 3 to 65, and 13 of them are from the Southern 260

China Guangdong province (Supplementary Table 5 ). It is not clear how the age and 261 geographic location contributed to the diverse SARS-Cov-2 cellular immunity. 262 14 intensity to each viral antigens and individual age, there was a trend that the cellular 264 immune response increased in subjects over 30 years of age ( Supplementary Fig. 2) . 265

However, due to the limited subjects, the significance of this age factor awaits further 266

The SARS-CoV-2 virus is still evloving during the global pandemic (30) guidelines. PBMCs were isolated using Ficoll-Paque plus (GE Healthcare, Shanghai Co.

The eleven overlapping pentadecamer peptides of the SARS-CoV-2 viral 305 proteins were synthesized at >95% purity from Shanghai Royobiotech Co., LTD, 4°C for 20 min. Unrelated peptide group was included as a negative control for 359 spontaneous CD107a release and/or cytokine production. 360

Statistical analysis was performed based on student's t test for two group analysis. 363 P value less than 0.05 is considered statistically significant. 

Clinical 384 features of patients infected with 2019 novel coronavirus in Wuhan